85. 特発性間質性肺炎
[臨床試験数:514,薬物数:377(DrugBank:108),標的遺伝子数:97,標的パスウェイ数:204

Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04030026
(ClinicalTrials.gov)
August 8, 201911/7/2019A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of CoughPhase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of CoughNalbuphine;Idiopathic Pulmonary Fibrosis;CoughDrug: Nalbuphine ER;Drug: Placebo oral tabletTrevi TherapeuticsParexelRecruiting18 Years80 YearsAll60Phase 2United Kingdom
2EUCTR2018-004744-31-GB
(EUCTR)
24/06/201905/03/2019Efficacy and Safety Study: Nalbuphine ER Tablets for the Treatment of Cough in Idiopathic Pulmonary FibrosisA Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis With Nalbuphine ER Tablets for the Treatment of Cough - CANAL Treatment of Cough in Idiopathic Pulmonary Fibrosis;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]Product Name: Nalbuphine Extended-Realease (ER) Tablets
Product Code: TR0311
INN or Proposed INN: Nalbuphine
Other descriptive name: NALBUPHINE HYDROCHLORIDE
Product Name: Nalbuphine Extended-Release (ER) Tablets
Product Code: TR0311
INN or Proposed INN: Nalbuphine
Other descriptive name: NALBUPHINE HYDROCHLORIDE
Product Name: Nalbuphine Extended-Release (ER) Tablets
Product Code: TR0311
INN or Proposed INN: Nalbuphine
Other descriptive name: NALBUPHINE HYDROCHLORIDE
Product Name: Nalbuphine Extended-Release (ER) Tablets
Product Code: TR0311
INN or Proposed INN: Nalbuphine
Other descriptive name: NALBUPHINE HYDROCHLORIDE
Trevi Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2United Kingdom